Jean Jacques Bienaime - May 9, 2024 Form 4 Insider Report for BIOMARIN PHARMACEUTICAL INC (BMRN)

Role
Director
Signature
/s/ Tae Sang Yoo, Attorney-in-Fact
Stock symbol
BMRN
Transactions as of
May 9, 2024
Transactions value $
-$731,200
Form type
4
Date filed
5/13/2024, 03:57 PM
Previous filing
Apr 15, 2024
Next filing
May 21, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction BMRN Common Stock +Options Exercise $1,262,000 +20,000 +4.21% $63.10 494,994 May 9, 2024 Direct F1
transaction BMRN Common Stock -Sell -$1,632,400 -20,000 -4.04% $81.62 474,994 May 9, 2024 Direct F1
transaction BMRN Common Stock +Options Exercise $1,262,000 +20,000 +4.21% $63.10 494,994 May 10, 2024 Direct F1
transaction BMRN Common Stock -Sell -$1,622,800 -20,000 -4.04% $81.14 474,994 May 10, 2024 Direct F1
holding BMRN Common Stock 247,333 May 9, 2024 Shares held by Jean-Jacques Bienaime Family Trust
holding BMRN Common Stock 100 May 9, 2024 Shares held as UTMA custodian for child 1
holding BMRN Common Stock 100 May 9, 2024 Shares held as UTMA custodian for child 2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BMRN Stock Option (Right to Buy Common Stock) -Options Exercise $0 -20,000 -21.98% $0.00 71,000 May 9, 2024 Common Stock 20,000 $63.10 Direct F2
transaction BMRN Stock Option (Right to Buy Common Stock) -Options Exercise $0 -20,000 -28.17% $0.00 51,000 May 10, 2024 Common Stock 20,000 $63.10 Direct F2

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Trade made pursuant to a 10b5-1 plan executed on August 7, 2023.
F2 Reflects the number of options outstanding after the transactions from this specific stock option grant.